Atea Pharmaceuticals, Inc.
AVIR evidence brief
What we can confirm
- Market Cap:
- $455.6M
What it means
What to watch
Prepared research question
What matters most for AVIR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVIR
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing oral antiviral therapies, with a lead hepatitis C virus (HCV) regimen of bemnifosbuvir and ruzasvir in Phase 3 trials and an early-stage candidate for hepatitis E virus.
Key risk: No product revenue
Market Cap
$455.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 10 clinical trials for Atea Pharmaceuticals, Inc..
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing oral antiviral therapies, with a lead hepatitis C virus (HCV) regimen of bemnifosbuvir and ruzasvir in Phase 3 trials and an early-stage candidate for hepatitis E virus.
- Lead HCV regimen (bemnifosbuvir/ruzasvir) achieved a 98% sustained virologic response in Phase 2 per-protocol patients [sec].
- Phase 3 C-BEYOND trial met primary and secondary endpoints with an 8-week duration for non-cirrhotic patients [news].
- Phase 3 C-FORWARD trial topline results expected early Q1 2027 [news].
- Cash, cash equivalents, and marketable securities of $219.5 million as of June 30, 2026 [sec_mda].
- Net income of -$32.9 million for the latest reported period as of June 30, 2026 [sec].
What works
- Phase 2 data for the HCV regimen showed a 98% sustained virologic response among per-protocol patients, suggesting strong efficacy [sec].
- The regimen has demonstrated a favorable tolerability and drug-drug interaction profile with no food effect, supporting convenient dosing [sec].
- The global HCV therapeutics market remains substantial, with approximately $2.5 billion in net sales in 2025, indicating ongoing commercial opportunity [sec].
- The company initiated a Phase 1 trial for AT-587 in HEV, a condition with no approved therapies and significant unmet need [sec_mda].
What to weigh
- The company has no approved products and has not generated any product revenue to date [sec_mda].
- Additional substantial capital is likely required to complete Phase 3 trials and fund operations; the company anticipates needing to raise more capital [sec_mda].
- The next $10.0 million milestone payment to Merck is contingent on FDA acceptance of an NDA, which may be due as early as September 2027, adding financial obligation [sec_mda].
- Completion of the C-FORWARD trial and subsequent NDA submission is uncertain and subject to clinical and regulatory risks [sec_mda].
From the filings
Quoted directly from source documents.
High efficacy in Phase 2 for HCV regimen
“Results from our Phase 2 trial demonstrated a 98% sustained virologic response at 12 weeks post‑treatment among per‑protocol, treatment‑adherent patients following eight weeks of therapy.”
SEC filings · April 27, 2026
Phase 3 C-BEYOND trial met primary and secondary endpoints
“Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV”
News · August 12, 2026
Cash position as of June 30, 2026
“We had $219.5 million in cash, cash equivalents and marketable securities at June 30, 2026.”
SEC MD&A · August 12, 2026
Milestone payment upon FDA NDA acceptance
“The next potential milestone, in the amount of $10.0 million, is payable upon acceptance by the FDA of a new drug application covering a product candidate including ruzasvir.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2027-Q1 · Phase 3 C-FORWARD topline results — Results will inform the efficacy and safety of the HCV regimen and potential NDA submission.
Risks & what to watch (4)›
Key risks
- No product revenue — Company has not generated any product revenue and does not expect to in the foreseeable future [sec_mda].
- Need for additional capital — Substantial additional capital required; company may need to raise funds through equity or debt [sec_mda].
- Clinical trial execution risk — Phase 3 C-FORWARD trial and NDA submission subject to uncertainties [sec_mda].
- Milestone payment obligation — $10 million milestone due upon FDA NDA acceptance, adding financial pressure [sec_mda].
What to watch
- Topline results from Phase 3 C-FORWARD trial expected early Q1 2027 [news].
- Progress of the Phase 1 trial for AT-587 in hepatitis E virus [sec_mda].
- FDA acceptance of the NDA for the HCV regimen, triggering a $10 million milestone [sec_mda].
- Cash burn rate and potential for additional financing needs [sec_mda].
Sources: News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Atea Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Atea Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 12.1%
- Days to cover
- 24.4
- Shares short
- 7,488,888
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVIR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Atea Pharmaceuticals, Inc.?
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing oral antiviral therapies, with a lead hepatitis C virus (HCV) regimen of bemnifosbuvir and ruzasvir in Phase 3 trials and an early-stage candidate for hepatitis E virus.
Who is the CEO of Atea Pharmaceuticals, Inc.?
Dr. Jean-Pierre Sommadossi Ph.D. is the chief executive officer of Atea Pharmaceuticals, Inc. (AVIR).
Where is Atea Pharmaceuticals, Inc. headquartered?
Atea Pharmaceuticals, Inc. (AVIR) is headquartered in Boston, MA, United States.
What therapeutic areas does Atea Pharmaceuticals, Inc. focus on?
Atea Pharmaceuticals, Inc. develops therapies across Oncology, Infectious Disease, Respiratory, Nephrology, Gastroenterology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.